Skip to Content

Tuesday, January 22nd, 2019

Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3

Closed
by January 8, 2019 PRESS RELEASES
  • Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-in-class agent
Previous
Next